<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652700</url>
  </required_header>
  <id_info>
    <org_study_id>8591-024</org_study_id>
    <secondary_id>MK-8591-024</secondary_id>
    <secondary_id>2020-003309-79</secondary_id>
    <secondary_id>jRCT2031200419</secondary_id>
    <nct_id>NCT04652700</nct_id>
  </id_info>
  <brief_title>Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024)</brief_title>
  <acronym>Impower-024</acronym>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate the efficacy and safety of oral Islatravir (ISL)&#xD;
      once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men&#xD;
      (MSM) and transgender women (TGW) who have sex with men and who are at high risk of HIV-1&#xD;
      infection with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks&#xD;
      of follow-up after randomization. The primary hypothesis of the study is that the&#xD;
      administration of ISL QM as PreP reduces the incidence rate per year of the confirmed HIV-1&#xD;
      infections compared to the background incidence rates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">September 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind with in-house blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate Per Year of Confirmed Human Immunodeficiency Virus 1 (HIV-1) Infection</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status. The primary analysis will compare the incidence rate per year of confirmed HIV-1 Infections between the ISL QM arm participants and the background incidence rate calculated from screened participants. HIV serology tests and polymerase chain reaction (PCR) tests will be done at pre-specified timepoints to confirm HIV-1 infection. The background incidence rate will be estimated using tests based on biomarkers that can differentiate recent from non-recent infections in the population screened for this study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 26 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE will be reported for each treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE will be reported for each treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate Per Year of Confirmed HIV-1 infection Among Participants</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status. The secondary incidence analysis to compare the incidence rate per year of confirmed HIV-1 Infections between the ISL QM arm and the FTC/TDF or FTC/TAF QD arm participants. HIV serology tests and PCR tests will be done at pre-specified timepoints to confirm HIV-1 infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>HIV Preexposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Islatravir (ISL) Once Monthly (QM) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTC/TDF or FTC/TAF QD Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISL</intervention_name>
    <description>ISL 60 mg tablet, QM, orally for up to 24 months</description>
    <arm_group_label>Islatravir (ISL) Once Monthly (QM) Group</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF</intervention_name>
    <description>Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally for up to 24 months</description>
    <arm_group_label>FTC/TDF or FTC/TAF QD Group</arm_group_label>
    <other_name>Truvada</other_name>
    <other_name>Emtricitabine/Tenofovir Disoproxil Fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TAF</intervention_name>
    <description>Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months</description>
    <arm_group_label>FTC/TDF or FTC/TAF QD Group</arm_group_label>
    <other_name>Descovy</other_name>
    <other_name>Emtricitabine/Tenofovir Alafenamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ISL</intervention_name>
    <description>Placebo ISL 0 mg tablets QM, orally for up to 24 months.</description>
    <arm_group_label>FTC/TDF or FTC/TAF QD Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to FTC/TDF</intervention_name>
    <description>Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months</description>
    <arm_group_label>Islatravir (ISL) Once Monthly (QM) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to FTC/TAF</intervention_name>
    <description>Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months</description>
    <arm_group_label>Islatravir (ISL) Once Monthly (QM) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has confirmed Human Immunodeficiency Virus (HIV) uninfected based on negative&#xD;
             HIV-1/HIV-2 test result before randomization&#xD;
&#xD;
          -  Is sexually active with male or transgender women (TGW) partners defined as having&#xD;
             anal sexual intercourse with a man or TGW at least once in the past month&#xD;
&#xD;
          -  Is at high risk for sexually acquiring HIV-1 infection based on self-report of at&#xD;
             least 1 of the following: a) Condomless receptive anal intercourse in the 6 months&#xD;
             prior to screening occurring outside a mutually monogamous HIV seronegative concordant&#xD;
             relationship b) More than 5 partners (anal intercourse) in the 6 months prior to&#xD;
             screening c) Any unprescribed stimulant drug use in the 6 months prior to screening d)&#xD;
             Rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior&#xD;
             to screening&#xD;
&#xD;
          -  Participants 16 or 17 years of age must weigh ≥35 kg. Enrollment for 16- to&#xD;
             17-year-old participants will begin only after completion of the Sentinel Cohort IA&#xD;
             and review of IA results by the external data monitoring committee (eDMC)&#xD;
&#xD;
          -  Has no plans to relocate or travel away from the site for ≥4 consecutive weeks during&#xD;
             study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has hypersensitivity or other contraindication to any component of the study&#xD;
             interventions as determined by the investigator&#xD;
&#xD;
          -  Has chronic HBV infection or past HBV infection which could indicate risk for&#xD;
             Hepatitis B reactivation&#xD;
&#xD;
          -  Has known current or chronic history of liver disease or known hepatic or biliary&#xD;
             abnormalities, unless the participant has stable liver function tests and no evidence&#xD;
             of hepatic synthetic dysfunction&#xD;
&#xD;
          -  Has a history of malignancy within 5 years of screening except for adequately treated&#xD;
             basal cell or squamous cell skin cancer or in situ anal cancers&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, laboratory abnormality or&#xD;
             other circumstance that might, in the opinion of the investigator, confound the&#xD;
             results of the study or interfere with the participant's participation for the full&#xD;
             duration of the study, such that it is not in the best interest of the participant to&#xD;
             enroll&#xD;
&#xD;
          -  Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product&#xD;
             at any time&#xD;
&#xD;
          -  Is currently receiving or is anticipated to require any prohibited therapies outlined&#xD;
             in the study from 30 days prior to Day 1 through the duration of the study&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional or prevention&#xD;
             clinical study with an investigational compound or device, within 30 days prior to Day&#xD;
             1 through the duration of the study&#xD;
&#xD;
          -  Has exclusionary laboratory values within 45 days prior to Day 1&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male participants and transgender women (TGW) who are at high risk for HIV-1 infection</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0007)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-934-7492</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Center for Clinical AIDS Research and Education ( Site 0011)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-557-3798</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Research Institute ( Site 0031)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-562-0163</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bridge HIV - San Francisco Department of Public Health ( Site 0003)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>628-217-7400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The GW Medical Faculty Associates-Medicine ( Site 0033)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-222-5727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center ( Site 0014)</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>772-519-0642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Infectious Disease ( Site 0029)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-413-7546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 0010)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>40764739602115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ponce De Leon Center Grady Health ( Site 0032)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-251-8940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center ( Site 0004)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-572-5116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center ( Site 0012)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-815-5009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey Medical School-Clinical Research Center ( Site 0017)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-972-3729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill ( Site 0019)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-843-2723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research ( Site 0002)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>512-480-9660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center ( Site 0025)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-948-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis-Infectious Diseases and tropical diseases ( Site 0151)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine ( Site 0101)</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <zip>1628655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>81332027181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Via Libre ( Site 0404)</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5113306717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0203)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27 11 989 9743</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute (WRHI)-Research Center ( Site 0201)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27113585300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation ( Site 0202)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27 (0)21 6504324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University-Pediatrics ( Site 0051)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+66896658846</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIV Netherlands Australia Thailand Research Collaboration ( Site 0056)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6626523040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 0052</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+66815310775</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preexposure prophylaxis (PrEP)</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

